LGALS9 and COVID-19: Levels of gal-3 and gal-9 were reported to be upregulated only in patients with severe disease (40, 41), raising the possibility that circulating gal-3 or gal-9 can be valuable biomarkers for severe pneumonia in patients with COVID-19 (44, 45).